Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: A meta-analysis of randomised controlled trials

The Lancet

Volumn 384, Issue 9943, 2014, Pages 599-606

  Cavender, Matthew A ^a   Sabatine, Marc S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG; FIBRINOGEN RECEPTOR ANTAGONIST;

ANTICOAGULATION; ARTICLE; BLEEDING; COCHRANE LIBRARY; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; INCIDENCE; SYSTEMATIC REVIEW (TOPIC);

ANTICOAGULANTS; ANTITHROMBINS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84906266882     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61216-2     Document Type: Article

References (42)

1. GN Levine, ER Bates, JC Blankenship et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 122
2. AM Lincoff, JA Bittl, RA Harrington et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
3. GW Stone, HD White, EM Ohman et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 369 2007 907 919
4. GW Stone, B Witzenbichler, G Guagliumi et al. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
5. A Kastrati, FJ Neumann, J Mehilli et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med 359 2008 688 696
6. A Kastrati, FJ Neumann, S Schulz et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 365 2011 1980 1989
7. PG Steg, A van 't Hof, CW Hamm et al. Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
8. S Subherwal, EM Ohman, KW Mahaffey et al. Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches Am Heart J 165 2013 644 654 54 e1.
9. E Boersma, RA Harrington, DJ Moliterno et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
10. A Bellemain-Appaix, SA O'Connor, J Silvain for the ACTION Group Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis JAMA 308 2012 2507 2516
11. SD Wiviott, E Braunwald, CH McCabe for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001
12. L Wallentin, RC Becker, A Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
13. GW Stone, ME Bertrand, JW Moses et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial JAMA 297 2007 591 602
14. RP Giugliano, JA White, C Bode et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
15. JO Friedrich, NK Adhikari, J Beyene Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data BMC Med Res Methodol 7 2007 5
16. R DerSimonian, N Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
17. S Duval, RL Tweedie A nonparametric "trim and fill" method of assessing publication bias in meta-analysis J Am Stat Assoc 95 2000 89 98
18. AM Lincoff, NS Kleiman, K Kottke-Marchant et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am Heart J 143 2002 847 853
19. AM Lincoff, JA Bittl, NS Kleiman et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol 93 2004 1092 1096
20. CM Gibson, DA Morrow, SA Murphy et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 2006 2364 2373
21. D Tavano, G Visconti, D D'Andrea et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention Am J Cardiol 104 2009 1222 1228
22. DJ Moliterno for the TENACITY Steering Committee and Investigators A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial Catheter Cardiovasc Interv 77 2011 1001 1009
23. G Patti, V Pasceri, L D'Antonio et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study) Am J Cardiol 110 2012 478 484
24. NV Deshpande, R Pratiti, P Admane, D Mukherjee, HM Mardikar Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention Indian Heart J 64 2012 444 448
25. Han Y. Bivalirudin versus heparin monotherapy and glycoprotein IIb/IIIa plus heparin for patients with AMI undergoing coronary stenting (BRIGHT). China Interventional Therapeutics (CIT 2014); Shanghai, China; March 21, 2014.
26. A Shahzad, I Kemp, C Mars et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 2014 published online July 5. http://dx.doi.org/10.1016/S0140-6736(14)60924-7
27. Briguori C. Novel approaches in preventing or limiting events III - randomized comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting through the femoral approach (NAPLES III). Scientific Sessions of the American College of Cardiology; Washington, DC, USA; March 29-31, 2014.
28. R Mehran, SV Rao, DL Bhatt et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
29. JL Anderson, CD Adams, EM Antman for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 127 2013 e663 e828
30. PT O'Gara, FG Kushner, DD Ascheim for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 127 2013 e362 e425
31. G Tarantini, SJ Brener, A Barioli et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials Am Heart J 167 2014 401 12 e6
32. SJ Pocock, R Mehran, TC Clayton et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial Circulation 121 2010 43 51
33. FA Spencer, M Moscucci, CB Granger et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 116 2007 2793 2801
34. D Alexopoulos, I Xanthopoulou, V Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
35. DL Bhatt, RA Harrington for the CHAMPION PHOENIX Executive Committee and Investigators Platelet inhibition with cangrelor during PCI N Engl J Med 369 2013 393 394
36. KK Steinberg, SJ Smith, DF Stroup et al. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies Am J Epidemiol 145 1997 917 925
37. U Zeymer, A van 't Hof, J Adgey et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial Eur Heart J 2014 10.1093/eurheartj/ehu214 published online May 21.
38. AM Lincoff, NS Kleiman, DJ Kereiakes et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial JAMA 292 2004 696 703
39. S Schulz, J Mehilli, G Ndrepepa et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial Eur Heart J 31 2010 582 587
40. HD White, EM Ohman, AM Lincoff et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 52 2008 807 814
41. R Mehran, AJ Lansky, B Witzenbichler et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
42. S Schulz, A Kastrati, M Ferenc et al. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial EuroIntervention 9 2013 430 436